Biotechnology News and Research

RSS

BioMed Realty Trust announces financial results for fourth-quarter and full-year ended December 31, 2009

BioMed Realty Trust, Inc., a real estate investment trust focused on Providing Real Estate to the Life Science Industry®, today announced financial results for the fourth quarter and full-year ended December 31, 2009.

10 Feb 2010

Allylix raises $6M in first closing of Series C financing

Allylix Inc. announced today that it has raised $6 million in the first closing of its Series C financing. The money will allow the Company to commercialize its first three products for the food and fragrance industry, and allow it to advance several additional products in its pipeline.

10 Feb 2010

EMEA grants Genta's request for SME designation

Genta Incorporated announced that it has received $2.8 million in non-dilutive cash proceeds from the sale of net operating tax losses and research tax credits generated in prior tax years as part of the Technology Business Tax Certificate Program sponsored by the New Jersey Economic Development Authority (NJEDA), pursuant to the rules, regulations and stipulations set forth by the program.

10 Feb 2010

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.

10 Feb 2010

MDS to divest remaining MDS Pharma Services Early Stage business for $45M

MDS Inc., a leading provider of products and services to the global life sciences markets, today announced that it has signed agreements to divest its remaining MDS Pharma Services Early Stage business, which provides Discovery through Phase IIa clinical trial services to biotechnology and pharmaceutical companies, for $45 million and certain minority equity interests.

10 Feb 2010

Goodwin Biotechnology, Macrocyclics announce collaboration on Chelation and Bioconjugation

Goodwin Biotechnology Inc., a full service Contract Biomanufacturing Company and Macrocyclics, Inc., a manufacturer of customized chelating agents, jointly announced today their collaborative agreement on Chelation and Bioconjugation. The collaboration will strengthen joint customer projects in Nuclear Medicine involving Chelation, Bioconjugation and GMP manufacturing.

10 Feb 2010

Kinexus Bioinformatics announces the commercial release of Protein Kinase Microarray

Kinexus Bioinformatics Corporation announced the commercial release of its novel Protein Kinase Microarray with 200 recombinant human protein kinases for screening. The microarray has wide utility including applications for drug target counter screening, to identify novel kinase substrates, establish kinase antibody specificities, and for the discovery and testing of protein kinase-protein and protein kinase-compound interactions.

10 Feb 2010

Insight into mechanism H. pylori uses to evade the immune system

Helicobacter pylori (H. pylori) is the causal agent of chronic gastritis, ulcer and gastric cancer. It has the potential to persist in the human stomach for decades, sometimes causing neither harm nor clinical symptoms. Nevertheless, on some occasions, depending on the host immune system and the strain causing the infection, the outcome can be very serious. To maintain the infection, the bacterium must adapt to survive the host defences. One way to accomplish this is to sequentially change the external proteins on the bacterial surface.

10 Feb 2010

Glide Pharma to utilize $4.3M funding for progressing octreotide programme into clinical development

Glide Pharma, a specialty pharmaceutical company focused on the needle-free administration of solid dose therapeutics and vaccines, today announced that it has completed an oversubscribed GBP2.7 million ($4.3 million) investment round. The fundraising was supported by a number of existing institutional and private investors, including Hygea VCT and Oxford Technology VCTs. The company has now completed four successful investment rounds, securing funding totalling approximately GBP10 million.

10 Feb 2010

Sartorius releases preliminary unaudited figures for fiscal 2009

Today Sartorius, a leading international process and laboratory technology provider, released its preliminary unaudited figures for fiscal 2009. In the reporting period, business in both Group divisions showed substantially divergent trajectories.

From Sartorius 10 Feb 2010

PolyMedix provides overview of its 2010 clinical milestones

PolyMedix, Inc. (www.polymedix.com), an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, provided an overview of its 2010 clinical milestones in a presentation by President & C.E.O., Nicholas Landekic at the 2010 BIO CEO & Investor Conference.

10 Feb 2010

Vitrolife announces 14% increase in sales for fourth-quarter 2009

Sales increased by 14 percent during the fourth quarter and amounted to SEK 67 (59) million. Calculated in local currency growth was 15 percent. Sales for the year amounted to SEK 275 (225) million, corresponding to an increase of 22 percent. Calculated in local currencies growth was 10 percent.

10 Feb 2010

Sequenom CMM licenses rights from Optherion to develop and commercialize AMD diagnostic tests

Sequenom, Inc., today announced an exclusive worldwide licensing agreement with Optherion, Inc. Under the agreement, Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM), obtained the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD).

10 Feb 2010

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Elan Corporation, plc today reported its fourth quarter and full-year 2009 financial results and provides financial guidance for 2010.

10 Feb 2010

Sony acquires iCyt Mission Technology

Sony Corporation (Sony) announced today that it has acquired iCyt Mission Technology, Inc. (iCyt), a leading producer of high-performance cell sorters used for stem cell and disease research, through its U.S. subsidiary, Sony Corporation of America (SCA).

10 Feb 2010

BBSRC supports innovative research on limb control

New research at the University of Leicester into how the brain controls the movements of limbs could prompt major advances in understanding the human brain and the development of prosthetic limbs.

10 Feb 2010

SIRO Clinpharm announces alliance with DreamCIS CRO

SIRO Clinpharm, a Contract Research Organization (CRO) with a presence in India, Western and Central Eastern Europe, and the United States today announced its alliance with DreamCIS Inc., a leading CRO based in Seoul, South Korea.

9 Feb 2010

Whooping cough vaccine may be losing its punch: study

Vaccination programs against whooping cough may not be fully effective because the bacteria that cause the disease have evolved new strains, a new study has found.

9 Feb 2010

Chi-Fu Trading to market and sell Delcath PHP Systems in Taiwan

Delcath Systems, Inc. (DCTH), a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today the signing of its first research, distribution, sales and marketing agreement for its Percutaneous Hepatic Perfusion (PHP) System (the Delcath PHP System™). The agreement grants Chi-Fu Trading Co., Ltd. the exclusive right to market and sell the Delcath PHP System in Taiwan for hepatic malignancies and infectious disease upon Taiwan Food and Drug Administration (TFDA) approval, and any other approved use, with a conditional option for Singapore.

9 Feb 2010

Biogen Idec reports 2009 fourth quarter and full year earnings

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2009 results.

9 Feb 2010